Ruxolitinib was recently approved to treat acute graft-versus-host disease (GVHD), and trials are ongoing to understand the best way to use the treatment with transplantation, said David Snyder, MD, associate chair of the Department of Hematology & Hematopoietic Cell Transplantation at City of Hope.
Ruxolitinib was recently approved to treat acute graft-versus-host disease (GVHD), and trials are ongoing to understand the best way to use the treatment with transplantation, said David Snyder, MD, associate chair of the Department of Hematology & Hematopoietic Cell Transplantation at City of Hope.
Transcript
When does graft-versus-host disease occur, and what is the difference between acute and chronic graft-versus-host disease?
So, GVHD, or graft-versus-host disease is an immune reaction where the donor’s T lymphocytes recognize minor antigen differences on the surface of the cells of the patient and try to react against them. In a sense, the graft tries to reject the patient instead of the patient rejecting the graft.
We talk about acute and chronic GVHD. By definition, acute GVHD is any reaction that occurs within the first 100 days after transplant, and chronic GVHD is reactions that occur after 100 days. But that’s somewhat an oversimplification. There are some differences in the mechanism of those reactions and there can be overlap. So, some patients may have what looks like chronic GVHD earlier than day 100, and conversely some might have acute GVHD that comes on after day 100. But that remains one of the biggest challenges to success from transplantation, and fortunately there are some improvements being made.
Ironically, ruxolitinib, which is the drug we use as our JAK 2 inhibitor treating myelofibrosis, was just recently approved as treatment for refractory acute GVHD, so it does inhibit the JAK 2/STAT pathway, which is important in these inflammatory immune reactions, as well. We, and others, are trying to study what’s the best way to use JAK 2 inhibitors in the context of transplantation—in terms of pretransplant, peri-transplant, and posttransplant.
And we have a trial at City of Hope, where we’re giving our patients ruxolitinib from day minus 3 to day plus 30 of the transplant procedure to see what impact that might have on some of the morbidities that could occur, including the incidence of graft-versus-host disease.
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Dr Michael Farwell on FDG PET/CT Imaging to Predict Immunotherapy Response in Advanced Melanoma
April 15th 2024Michael Farwell, MD, associate professor of radiology at the Hospital of the University of Pennsylvania, provides insights into a study on the benefits of using 18F-fluorodeoxyglucose (FDG) PET/CT imaging to detect metabolic tumor changes in skin cancer.
Read More